Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial (GOIRC- 02-2024)

Copyright © 2025 Fullcro S.R.L. - TUTTI I DIRITTI RISERVATI
per contatti riguardanti lo Studio Immunostar mailto:immunostar@fullcro.org